IP Library › Granted Patent US 11,752,123
Granted Patent B2
US 11,752,123 · App. 17/157,139 · Granted Sep 12, 2023

Compositions comprising theanine, s-adenosylmethionine (SAMe), and/or

Inventors: Todd Henderson (Lancaster, SC); David Griffin (Forest Hill, MD); David Bledsoe (Lancaster, SC)
Assignee: NUTRAMAX LABORATORIES, INC.
A61K31/198A61K9/0053A61K31/197A61K31/4045A61K31/7076A61K36/575A61K36/756A61K38/018A61K38/38A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,752,123
App. No.
17/157,139
Granted
Sep 12, 2023
Kind
B2
Abstract

An anxiolytic composition includes a synergistic combination of one or more of an L-theanine, an s-adenosylmethionine (SAMe), and optionally an extract of Magnolia , an extract of Phellodendron , and a whey protein.

Claims (10)

1. An anxiolytic composition, comprising a synergistic combination of L-theanine and s-adenosylmethionine (SAMe) at a ratio of about 1.1:1, wherein the synergistic combination provides an anxiolytic change in a release pattern of one or more neurotransmitters.

2. The anxiolytic composition of claim 1 , wherein the neurotransmitters are brain neurotransmitters selected from the group consisting of glutamate and γ-aminobutyric acid (GABA).

3. The anxiolytic composition of claim 1 , formulated for oral administration to a mammal.

4. The anxiolytic composition of claim 1 , wherein the s-adenosylmethionine (SAMe) comprises a SAMe phytate salt.

5. The anxiolytic composition of claim 1 , further comprising an extract of magnolia and an extract of phellodendron.

6. An anxiolytic composition, comprising a synergistic combination of L-theanine in an amount of at least 2.0 mg and s-adenosylmethionine (SAMe) in an amount of at least 1.0 mg, wherein the synergistic combination provides an anxiolytic change in a release pattern of one or more neurotransmitters.

7. The anxiolytic composition of claim 6 , wherein the neurotransmitters are brain neurotransmitters selected from the group consisting of glutamate and γ-aminobutyric acid (GABA).

8. The anxiolytic composition of claim 6 , formulated for oral administration to a mammal.

9. The anxiolytic composition of claim 6 , wherein the s-adenosylmethionine (SAMe) comprises a SAMe phytate salt.

10. The anxiolytic composition of claim 6 , further comprising an extract of magnolia and an extract of phellodendron.

Continuity (5)
Continuation 16437701 · Jun 11, 2019
Continuation 15705435 · Sep 15, 2017
Continuation PCTUS2016049630 · Aug 31, 2016
Provisional Application 62212080 · Aug 31, 2015
Related Publication 20210137870A1 · May 13, 2021